AbbVie Inc (NYSE:ABBV) Claims Top Spot In Pharmaceutical TV Ad Spending

AbbVie Inc

According to the latest data from, AbbVie Inc (NYSE:ABBV) has taken the top spot for the most TV ad spending by a pharmaceutical brand or product for the month of September with Humira.

Story continues below

Humira Claiming Top Spot

AbbVie has spent $32.30 million last month for the TV ad campaign of Humira for three different indications— arthritis, psoriasis, and ulcerative colitis (UC).

This indicates a significant increase in the company’s TV ad spending for its anti-inflammatory drug from an estimated spending of $26.90 million in August.

Earlier this year, the company has presented encouraging data from the Phase 3 clinical trial evaluating Humira for the treatment of adult patients with moderate-to-severe fingernail psoriasis.

“This research reinforces our commitment to identifying solutions for serious unmet medical needs in dermatology,” reiterated John Medich, Ph.D., AbbVie Vice President (VP) of Clinical Development and Immunology.

Pharmaceutical TV Ad Spending for September

Placing second for September is Pfizer Inc (NYSE:PFE), having spent $21.40 million for the TV ad campaign of Lyrica. This is down from the previous month’s spending of $26.20 million for the seizure drug.

New drug TV ad campaigns that made it to last month’s top 10 include Invokana, which has placed third; Latuda, which has placed fourth; Cialis, which has placed fifth; and Viagra, which has placed ninth.

Johnson & Johnson (NYSE:JNJ) has spent $17.80 million for the TV ad campaign of its SGLT2 diabetes drug, Invokana; Sunovion Pharmaceuticals, Inc. has spent $15.90 million for the TV ad campaign of its antipsychotic drug, Latuda; and Eli Lilly and Co (NYSE:LLY) has spent $11.80 million for the TV ad campaign of its erectile dysfunction treatment, Cialis.

A new dry eye disease awareness campaign from Shire PLC (ADR) (NASDAQ:SHPG) has placed 10th with an estimated spending of $9.90 million.

Rejoining the top 10 list— aside from Humira and Lyrica— are Xeljanz XR, Trintellix, and Eliquis.

AbbVie has ended Monday’s session at $63.31; Pfizer at $33.61; Johnson & Johnson at $119.80; Eli Lilly at $83.06; and Shire at $197.70.

An ad to help with our costs